Galmed Pharmaceuticals Ltd.
GLMD
$1.07
$0.1111.59%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -20.74% | 52.76% | -17.75% | -44.47% | 39.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.18% | 72.59% | -9.78% | -23.57% | 36.99% |
| Operating Income | -4.18% | -72.59% | 9.78% | 23.57% | -36.99% |
| Income Before Tax | 1.15% | -122.97% | 13.41% | -59.18% | -29.94% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1.15% | -122.97% | 13.41% | -59.18% | -29.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.15% | -122.97% | 13.41% | -59.18% | -29.94% |
| EBIT | -4.18% | -72.59% | 9.78% | 23.57% | -36.99% |
| EBITDA | -3.15% | -81.91% | 10.68% | 23.36% | -37.74% |
| EPS Basic | 84.98% | 61.72% | 70.40% | 88.19% | 58.02% |
| Normalized Basic EPS | 84.98% | 69.79% | 70.40% | 91.23% | 58.02% |
| EPS Diluted | 84.98% | 61.72% | 70.40% | 88.19% | 58.02% |
| Normalized Diluted EPS | 84.98% | 69.79% | 70.40% | 91.23% | 58.02% |
| Average Basic Shares Outstanding | 558.29% | 482.42% | 192.52% | 1,248.15% | 209.51% |
| Average Diluted Shares Outstanding | 558.29% | 482.42% | 192.52% | 1,248.15% | 209.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |